Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

Introduction Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in systemic lupus erythematosus(SLE) patients. Our aim was to investigate the differences between SLE patients according to the presence of aPL and/or clinical antiphospholipid syndrome (APS)....

Descripción completa

Detalles Bibliográficos
Autores: Riancho-Zarrabeitia, L, Martinez-Taboada, V, Rua-Figueroa, I, Alonso, F, Galindo-Izquierdo, M, Ovalles, J, Olive-Marques, A, Fernandez-Nebro, A, Calvo-Alen, J, Menor-Almagro, R, Tomero-Muriel, E, Uriarte-Isacelaya, E, Botenau, A, Andres, M, Freire-Gonzalez, M, Soler, GS, Ruiz-Lucea, E, Ibanez-Barcelo, M, Castellvi, I, Galisteo, C, Vila, VQ, Raya, E, Narvaez-Garcia, J, Exposito, L, Hernandez-Beriain, JA, Horcada, L, Aurrecoechea, E, Pego-Reigosa, JM
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p2485
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/2485
Access Level:acceso abierto
Palabra clave:Antiphospholipid antibody
lupus anticoagulant
antiphospholipid syndrome
systemic lupus erythematosus
id ES_a759b65ef51eec55ed63abc17f0e85e2
oai_identifier_str oai:i3pt.fundanetsuite.com:p2485
network_acronym_str ES
network_name_str España
repository_id_str
spelling Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortalityRiancho-Zarrabeitia, LMartinez-Taboada, VRua-Figueroa, IAlonso, FGalindo-Izquierdo, MOvalles, JOlive-Marques, AFernandez-Nebro, ACalvo-Alen, JMenor-Almagro, RTomero-Muriel, EUriarte-Isacelaya, EBotenau, AAndres, MFreire-Gonzalez, MSoler, GSRuiz-Lucea, EIbanez-Barcelo, MCastellvi, IGalisteo, CVila, VQRaya, ENarvaez-Garcia, JExposito, LHernandez-Beriain, JAHorcada, LAurrecoechea, EPego-Reigosa, JMAntiphospholipid antibodylupus anticoagulantantiphospholipid syndromesystemic lupus erythematosusIntroduction Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in systemic lupus erythematosus(SLE) patients. Our aim was to investigate the differences between SLE patients according to the presence of aPL and/or clinical antiphospholipid syndrome (APS). Materials and methods Patients from the RELESSER-T registry were included. RELESSER-T is a Spanish multicenter, hospital-based, retrospective, SLE registry. Results We included 2398 SLE patients, 1372 of whom were positive for aPL. Overall 1026 patients were classified as SLE, 555 as SLE-APS and817 as SLE-aPL. Regarding cardiovascular risk factors, SLE-APS patients had higher rates of hypertension, dyslipidemia and diabetes than those with SLE-aPL and SLE (p < 0.001). SLE-APS patients showed higher rates of neuropsychiatric, cardiac, pulmonary, renal and ophthalmological manifestations than the other groups (p < 0.001). SLE-APS patients presented greater damage accrual with higher SLICC values (1.9 +/- 2.2 in SLE-APS, 0.9 +/- 1.4 in SLE-aPL and 1.1 +/- 1.6 in SLE,p < 0.001) and more severe disease as defined by the Katz index (3 +/- 1.8 in SLE-APS, 2.7 +/- 1.7 in SLE-aPL and 2.6 +/- 1.6 in SLE,p < 0.001). SLE-APS patients showed higher mortality rates (p < 0.001). Conclusions SLE-APS patients exhibited more severe clinical profiles with higher frequencies of major organ involvement, greater damage accrual and higher mortality than SLE-aPL and SLE patients.SAGE PUBLICATIONS LTD2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/2485LUPUSISSN: 09612033ISSNe: 14770962reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p24852026-06-21T15:30:37Z
dc.title.none.fl_str_mv Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
title Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
spellingShingle Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
Riancho-Zarrabeitia, L
Antiphospholipid antibody
lupus anticoagulant
antiphospholipid syndrome
systemic lupus erythematosus
title_short Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
title_full Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
title_fullStr Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
title_full_unstemmed Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
title_sort Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
dc.creator.none.fl_str_mv Riancho-Zarrabeitia, L
Martinez-Taboada, V
Rua-Figueroa, I
Alonso, F
Galindo-Izquierdo, M
Ovalles, J
Olive-Marques, A
Fernandez-Nebro, A
Calvo-Alen, J
Menor-Almagro, R
Tomero-Muriel, E
Uriarte-Isacelaya, E
Botenau, A
Andres, M
Freire-Gonzalez, M
Soler, GS
Ruiz-Lucea, E
Ibanez-Barcelo, M
Castellvi, I
Galisteo, C
Vila, VQ
Raya, E
Narvaez-Garcia, J
Exposito, L
Hernandez-Beriain, JA
Horcada, L
Aurrecoechea, E
Pego-Reigosa, JM
author Riancho-Zarrabeitia, L
author_facet Riancho-Zarrabeitia, L
Martinez-Taboada, V
Rua-Figueroa, I
Alonso, F
Galindo-Izquierdo, M
Ovalles, J
Olive-Marques, A
Fernandez-Nebro, A
Calvo-Alen, J
Menor-Almagro, R
Tomero-Muriel, E
Uriarte-Isacelaya, E
Botenau, A
Andres, M
Freire-Gonzalez, M
Soler, GS
Ruiz-Lucea, E
Ibanez-Barcelo, M
Castellvi, I
Galisteo, C
Vila, VQ
Raya, E
Narvaez-Garcia, J
Exposito, L
Hernandez-Beriain, JA
Horcada, L
Aurrecoechea, E
Pego-Reigosa, JM
author_role author
author2 Martinez-Taboada, V
Rua-Figueroa, I
Alonso, F
Galindo-Izquierdo, M
Ovalles, J
Olive-Marques, A
Fernandez-Nebro, A
Calvo-Alen, J
Menor-Almagro, R
Tomero-Muriel, E
Uriarte-Isacelaya, E
Botenau, A
Andres, M
Freire-Gonzalez, M
Soler, GS
Ruiz-Lucea, E
Ibanez-Barcelo, M
Castellvi, I
Galisteo, C
Vila, VQ
Raya, E
Narvaez-Garcia, J
Exposito, L
Hernandez-Beriain, JA
Horcada, L
Aurrecoechea, E
Pego-Reigosa, JM
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Antiphospholipid antibody
lupus anticoagulant
antiphospholipid syndrome
systemic lupus erythematosus
topic Antiphospholipid antibody
lupus anticoagulant
antiphospholipid syndrome
systemic lupus erythematosus
description Introduction Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in systemic lupus erythematosus(SLE) patients. Our aim was to investigate the differences between SLE patients according to the presence of aPL and/or clinical antiphospholipid syndrome (APS). Materials and methods Patients from the RELESSER-T registry were included. RELESSER-T is a Spanish multicenter, hospital-based, retrospective, SLE registry. Results We included 2398 SLE patients, 1372 of whom were positive for aPL. Overall 1026 patients were classified as SLE, 555 as SLE-APS and817 as SLE-aPL. Regarding cardiovascular risk factors, SLE-APS patients had higher rates of hypertension, dyslipidemia and diabetes than those with SLE-aPL and SLE (p < 0.001). SLE-APS patients showed higher rates of neuropsychiatric, cardiac, pulmonary, renal and ophthalmological manifestations than the other groups (p < 0.001). SLE-APS patients presented greater damage accrual with higher SLICC values (1.9 +/- 2.2 in SLE-APS, 0.9 +/- 1.4 in SLE-aPL and 1.1 +/- 1.6 in SLE,p < 0.001) and more severe disease as defined by the Katz index (3 +/- 1.8 in SLE-APS, 2.7 +/- 1.7 in SLE-aPL and 2.6 +/- 1.6 in SLE,p < 0.001). SLE-APS patients showed higher mortality rates (p < 0.001). Conclusions SLE-APS patients exhibited more severe clinical profiles with higher frequencies of major organ involvement, greater damage accrual and higher mortality than SLE-aPL and SLE patients.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/2485
url https://i3pt.portalinvestigacion.com/publicaciones/2485
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SAGE PUBLICATIONS LTD
publisher.none.fl_str_mv SAGE PUBLICATIONS LTD
dc.source.none.fl_str_mv LUPUS
ISSN: 09612033
ISSNe: 14770962
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415771332935680
score 15,812429

Similares en LA Referencia